CHMP recommends just two new meds in Feb meeting
The committee also noted three extensions of pre-existing therapies.
Read More
Tag: highlights
Givlaari, Nubeqa among Jan CHMP decisions
The committee recommended fifteen medicines for approval at its first meeting of 2020, as well as six extensions of current indications.
Read More
CHMP recommends five new medicines
Stelara, Keytruda and Tecentriq were also among the extensions of therapeutic indication.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
